In a significant milestone for cancer treatment in China, the Lecheng Pengbo (Hainan) BNCT Hospital has successfully completed its first boron neutron capture therapy (BNCT) for Mr. Xue, a 56-year-old advanced tongue cancer patient from Henan Province. This pioneering treatment represents not only a personal victory for Mr. Xue but also a quantum leap in radiation oncology for head and neck cancers.

Medical Triumph: Mr. Xue’s case marks the first approved BNCT treatment for tongue cancer in China, showcasing the potential of this cutting-edge technology to treat tumors that are surgically challenging or resistant to conventional therapies.

Patient Journey: From Despair to Hope

Mr. Xue’s medical odyssey began two years ago when he was diagnosed with stage IV squamous cell carcinoma of the tongue. After multiple surgeries, radiotherapy cycles, and chemotherapy sessions in his home province of Henan, his cancer continued to aggressively recur. “The pain was unbearable,” Mr. Xue recounted. “Eating became impossible, and I had lost all hope until I learned about BNCT.”

His journey to Hainan’s Boao Lecheng International Medical Tourism Pilot Zone wasn’t merely a geographical shift but a paradigm shift in cancer treatment philosophy. The BNCT approach offered a fundamentally different mechanism for destroying cancer cells while sparing healthy tissue – a critical advantage for tongue cancer where preserving function is paramount.

What Makes BNCT Revolutionary?

Boron Neutron Capture Therapy operates on an ingenious principle:

  1. Precision Targeting: A boron-10 compound is administered that selectively accumulates in cancer cells
  2. Neutron Irradiation: The tumor site is irradiated with epithermal neutrons
  3. Microscopic Detonation: When boron atoms capture neutrons, they split into lithium nuclei and alpha particles that destroy the cancer cell from within

“BNCT is like having microscopic suicide bombers that target only cancer cells. The alpha particles travel just 5-9 microns – about the width of a single cell – meaning adjacent healthy tissues remain virtually untouched,” explained Dr. Li Wei, Chief Oncologist at Lecheng BNCT Hospital.

This cellular precision is particularly valuable for tongue cancer treatment, where preserving nerve function, taste buds, and muscular integrity dramatically impacts quality of life post-treatment. Conventional radiation often causes permanent damage to these delicate structures.

The Treatment Protocol

Mr. Xue’s treatment involved a meticulously planned protocol:

  1. Pre-treatment Imaging: Advanced PET-CT and MRI scans precisely mapped tumor boundaries
  2. Boron Compound Administration: A specially formulated boron-phenylalanine (BPA) infusion delivered over 2 hours
  3. Real-time Monitoring: Constant blood boron level measurements ensured optimal tumor saturation
  4. Neutron Irradiation: A single 50-minute session using the hospital’s state-of-the-art accelerator-based neutron source

Remarkably, unlike conventional radiation that requires weeks of daily sessions, BNCT achieved its biological effect in a single treatment. “We observed tumor shrinkage within 72 hours and significant pain reduction almost immediately,” noted Dr. Zhang Min, the lead physicist on the case.

Why Lecheng? The Hainan Advantage

The Boao Lecheng International Medical Tourism Pilot Zone operates under special regulatory frameworks that allow:

  • Accelerated approval of internationally developed medical technologies
  • Utilization of drugs and equipment not yet available elsewhere in China
  • Multidisciplinary international medical collaboration

Lecheng Pengbo BNCT Hospital houses China’s first hospital-based accelerator neutron source specifically designed for BNCT. “Our neutron beam parameters are optimized for deep-seated tumors like tongue cancer,” emphasized Professor Chen Hao, Director of Nuclear Medicine. “The beam shaping assembly ensures maximum tumor dose while protecting critical structures like the spinal cord.”

Future Implications

Mr. Xue’s successful treatment opens new horizons for several challenging cancers:

  • Recurrent head and neck cancers: Where surgery and re-irradiation carry high complication risks
  • Glioblastoma: Brain tumors where precision is non-negotiable
  • Melanoma metastases: Which show exceptional boron uptake

“This isn’t just about one patient’s recovery. BNCT represents a fundamental shift in how we conceptualize cancer treatment – moving from broad assault to precision elimination. We’re entering an era where we can destroy cancer cell by cell without poisoning the entire body,” reflected Dr. Li.

As Mr. Xue returns to Henan with renewed hope, his case establishes BNCT as a viable option for patients who have exhausted conventional treatments. The Lecheng team is now expanding their protocols to include other challenging malignancies, potentially transforming terminal cancer diagnoses into manageable conditions.